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Abstract
Prions are infectious proteins that possess multiple self-propagating structures. The infor-
mation for strains and structural specific barriers appears to be contained exclusively in the
folding of the pathological isoform, PrPSc. Many recent studies determined that de novo
prion strains could be generated in vitro from the structural conversion of recombinant (rec)
prion protein (PrP) into amyloidal structures. Our aim was to elucidate the conformational
diversity of pathological recPrP amyloids and their biological activities, as well as to gain
novel insights in characterizing molecular events involved in mammalian prion conversion
and propagation. To this end we generated infectious materials that possess different con-
formational structures. Our methodology for the prion conversion of recPrP required only
purified rec full-length mouse (Mo) PrP and common chemicals. Neither infected brain
extracts nor amplified PrPSc were used. Following two different in vitro protocols recMoPrP
converted to amyloid fibrils without any seeding factor. Mouse hypothalamic GT1 and neu-
roblastoma N2a cell lines were infected with these amyloid preparations as fast screening
methodology to characterize the infectious materials. Remarkably, a large number of amy-
loid preparations were able to induce the conformational change of endogenous PrPC to
harbor several distinctive proteinase-resistant PrP forms. One such preparation was char-
acterized in vivo habouring a synthetic prion with novel strain specified neuropathological
and biochemical properties.
Author Summary
Prions are infectious proteins capable of acquiring multiple self-propagating structures.
The information for strains and structural specific barriers appears to be contained exclu-
sively in the folding of the pathological isoform, designated as PrPSc. During propagation,
disease-associated conformer PrPSc coerces the physiological form, denoted as PrPC, to
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adopt the pathological isoform conformation. We describe here the generation of an array
of infectious materials with different structural, morphological, biochemical and cell bio-
logical characteristics. After producing purified recombinant prion protein of the wild-
type mouse full-length sequence in Escherichia coli, we polymerized the protein into vari-
ous amyloid fibril conformations based on different amyloid preparations. We also applied
a build-in methodology for screening amyloid preparations and generate infectious mate-
rials using an amyloid-infected cell culture assay. Some of the amyloid fibrils preparations
were able to efficiently amplify in PMCA (Protein Misfolding Cyclic Amplification), and
to induce endogenous PrPC to convert into PrPSc in both murine hypothalamic GT1 and
neuroblastoma N2a cell lines. One such protocol lead to the generation of a novel synthetic
prion strain in mice.
Introduction
Prion diseases or transmissible spongiform encephalopathies are fatal neurodegenerative disor-
ders of humans and animals. During the course of these maladies the cellular prion protein
(PrPC) converts into an abnormally folded isoform, PrPSc, which accumulates in the central
nervous system (CNS), ultimately leading to the host death [1, 2]. The key molecular event of
these disorders is therefore the conformational change of PrPC from its physiological form into
the pathological structural isoform noted as prion or PrPSc. The physiological PrPC is a glyco-
sylphosphatidylinositol (GPI)-anchored protein present in all cell types. Unlike PrPSc, PrPC
has a high content of α-helix in its secondary structure. Differences in structural conformation
lead to different biological characteristics: while PrPC is soluble in detergents and sensitive to
proteinase K (PK) digestion, PrPSc is partially PK-resistant and insoluble in non-ionic deter-
gents [3]. Nevertheless, a sizeable fraction of PrPSc is sensitive to PK digestion [4] and is dis-
persed with detergent and/or sonication [5]. Moreover, Colby et al. reported that protease-
sensitive synthetic prions could be generated in vitro during polymerization of recombinant
PrP (recPrP) into amyloid fibers [6]. Recently, PK-sensitive and PK-resistant PrPSc were
shown to share a common structure and phenotype despite the differences in resistance to PK-
digestion, sediment and distribution of multimers [7, 8].
For most proteins, if not all, the same amino acid sequence can encipher numerous and dif-
ferent amyloid states [9, 10]. The ability of PrP to acquire multiple self-propagating structures
can thus explain the formation of multiple prion strains within the same host [11]. The infor-
mation for prions is enciphered in these structures by a distinct conformation of the pathologi-
cal isoform [12–14].
Synthetic prions were produced via in vitro induction of misfolding and aggregation of bac-
terially expressed recPrP [15]. This work clearly indicates that PrPSc is the sole component of
the infectious agent, which propagates by converting PrP into various misfolded forms [14–
16]. These first synthetic prions were produced injecting amyloid fibrils of recombinant mouse
PrP residues 89–230 (recMoPrP(89–230)) into transgenic (Tg) mice carrying the homologous
sequence. This endeavor opened new avenues in the structural characterization of infectious
prions [15]. An array of recPrP amyloids with varying conformation stability was produced,
showing a direct relationship between stability and incubation times of prion strains, at least in
mice. The conformational stabilities of the new synthetic prion strains and their incubation
periods seem to be dictated by the properties of the amyloid preparations from which they
were generated [16]. Although lacking both glycolsylation and the GPI anchor, secondary and
tertiary structures of refolded recPrP appear to be identical to those of brain-derived PrPC [17,
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18]. Remarkably, different amyloid preparations generated by recPrP can produce new prion
strains with novel neuropathological and biochemical features when injected in mice [14–16].
This approach provided a useful tool to further investigate the functional/structural relation-
ships of mammalian prions. In the last few years, different protocols have been established in
which recPrP was successfully converted into PrPSc by means of Protein Misfolding Cyclic
Amplification (PMCA) [19, 20]. This technique consists of cycles of sonication and incubation
which uses normal brain homogenate as source of PrPC [21]. The crystal structure of human
recPrP has revealed a possible mechanism for oligomerization in which the three-dimensional
swapping of the C-terminus helix 3 and the re-arrangement of the disulfide bond result in the
formation of a dimer [22, 23]. These data have suggested a possible role for a sulfhydryl-disul-
fide exchange reaction during the conversion of PrPC to PrPSc. Moreover, this mechanism has
been recapitulated in vitro by seeded conversion of hamster recPrP(90–231) truncated form
with an histidine tag (His-tag) to a disulfide-bonded oligomer by a reduction-oxidation
(REDOX) process [24].
We therefore established two different experimental procedures for amyloid preparations:
(i) REDOX process, and (ii) non-REDOX process, using full-length recMoPrP residue 23 to
231 (recMoPrP(23–231)). Our protocols for conversion of PrP required only purified full-
length recMoPrP and common chemicals. We were then able to produce 34 different amyloids.
Neither prion-infected brain extracts, nor amplified exogenous PrPSc were used. In both pro-
cesses, recMoPrP(23–231) converted to conformational structures of fibrils without any seeded
factor. The fibrils generated by the REDOX process most likely contained intermolecular disul-
fide bridge structures. In addition, the recMoPrP(23–231) amyloid preparations subjected to
the REDOX and non-REDOX in vitro processes exhibited different morphological and bio-
chemical prion characteristics. The ability of these amyloid preparations to behave as bona-fide
prion were assessed in vitro either in cell cultures or by means of PMCA.
First, we employed an amyloid-infected cell culture assay for screening amyloid prepara-
tions, in order to evaluate putative infectious materials [25]. Based on this methodology, when
infected into mouse hypothalamic (GT1) and mouse neuroblastoma (N2a) host cell lines [26],
amyloid fibrils from different preparations induced the conversion of endogenous PrPC to
mildly PK-resistant PrP isoforms. The various amyloid preparations also caused PrP to accu-
mulate and propagate in both membrane and cytosolic compartments of cultured neuronal
cells. Two of the amyloid preparations that were shown to efficiently propagate in cell culture
and produced under either REDOX or non-REDOX conditions, #28 and #4 respectively, were
assessed by means of PMCA. To this aim we used the brain of wild-type mice (CD1) as sub-
strate for amplification. Finally, these two preparations were intracerebrally injected (i.c.) into
CD1 mice to assess their ability to induce prion pathology in vivo. While preparation #28 did
not produce any evident prion pathology, isolate #4 was able to replicate and induce clinical
disease in wild-type CD1 mice harbouring distinctive neuropathological and biochemical
features.
Results
Generation of different recPrP amyloids
To generate recPrP amyloids with different conformations, we systematically altered the condi-
tions for their formation, including denaturant concentrations, pH and buffer composition (S1
and S2 Tables). The mechanism of amyloid formation determines significantly the amyloid
structure of recPrP. The protein has been known to convert to different types of amyloid and
some assemblies may be induced with the formation of intermolecular disulfide bonds leading
to domain-swapping [27, 28]. These alternative structures showed the coexistence of different
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molecular forms of PrP with the capacity of self-propagating prions [24]. In our experiments,
we started from different states of recMoPrP(23–231) using either REDOX or non-REDOX
processes. This resulted in different amyloid preparations in which the monomeric recMoPrP
(23–231) followed different pathways for more stable free energy states. We induced the
REDOX process by reducing disulfide bonds of recMoPrP(23–231) at high concentration of
reducing agent in the presence of 6M guanidine hydrochloride (Gdn-HCl), with or without the
addition of sodium chloride (NaCl). The concentration of all these components and of the pro-
tein was subsequently decreased by means of direct dilution to reach the final concentrations
for fibrillization reactions (S1 Fig). This process differs from the earlier protocol reported to
convert PrP in vitro [24], although sharing the same mechanism [27, 28]. In order to study the
converted ability and folding behaviors of recMoPrP(23–231), we analyzed the kinetics of puri-
fied recMoPrP(23–231) conversion into β-sheet-rich forms under different defined biophysical
and biochemical conditions (S1 and S2 Tables).
Morphological and biochemical characterization of recPrP amyloids
To monitor the amyloid formations, we used a thioflavin-T (ThT)-binding assay [29, 30].
Kinetic curves presented a sigmoidal shape, typically denoting an increased content of β-sheet
structures, as well as enhanced aggregation of monomeric recPrP (Fig 1A). These sigmoidal
curves highlighted a lag phase followed by rapid accumulation of fibrils (Figs 1B and S2). The
quantitative analysis of the lag phase was carried out by estimating the increase in ThT fluores-
cence intensity [31]. The end of the lag phase coincides with the point when ThT fluorescence
intensity started to increase. The maximum ThT fluorescence intensities exhibited a wide
range between the two amyloid preparation processes. In the non-REDOX process, the maxi-
mum intensities are higher than those of the REDOX process (Fig 1A). At neutral pH, the lag
phases for aggregation processes of recMoPrP(23–231) are shorter in comparison with acidic
pH 5 (S2 Fig). The shortest lag phase and most rapid production of amyloid were observed at
pH 7.4 (S2 Fig) (p<0.05, n = 12). Interestingly, the fibrillization showed that lag phases vary in
the presence of 2M Gdn-HCl between different conditions and also under the same conditions,
which were indicated with high error bar values (S2 Fig). These data suggest that at different
concentrations of Gdn-HCl, monomeric recMoPrP(23–231) explores many states of accessible
free energies [32]. At denaturant concentration less than 1M, production of amyloids was
observed only at pH 7.5 in the REDOX process, whereas no amyloid form was found at pH 5.0.
Differences in kinetic traces and maximum intensity values (Figs 1 and S2) were also
highlighted in terms of morphology, as revealed by atomic force microscopy (AFM) (Figs 2
and S3A).
To gain further insights into the aggregated morphology of the end products, we studied the
aggregated topology of all recMoPrP(23–231) amyloid preparations by AFM. The recMoPrP
(23–231) aggregation products were imaged at two end point times of fibrillization, i.e. 55
hours and 72 hours (Figs 2 and S3A). AFM scans of mica surfaces treated with different amy-
loid preparations showed that recMoPrP(23–231) aggregated after 72 hours and clearly
revealed marked morphological differences. The morphology-dependence of the fibrillizations
was observed at different concentrations of denaturant (S3B Fig). For example, at 4M Gdn-
HCl and 4M Gdn-HCl with NaCl in both REDOX and non-REDOX processes, the AFM analy-
ses displayed a relatively homogenous population of spherical particles (β-oligomers) [33] and
very short fibrils (approximately less than 0.5 μm) (Figs 2 and S3A). In both processes, at 2M
Gdn-HCl, 2M Gdn-HCl in the presence of NaCl and 3M Gdn-HCl alone, recMoPrP(23–231)
was converted to amyloid forms. These were visualized by AFM as fibrils, ranging from very
short to longer and more mature fibrils. The major fibrillar subtypes were straight, slightly
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curvy ribbons or rod-shaped fibrils (Figs 2 and S3A). These results are all in agreement with
earlier studies [34]. In order to ascertain whether some preparations were true amyloids, fur-
ther experiments were carried out to test their capability of seeding amyloid formation.
In our amyloid morphology analyses, different amyloid preparations of recMoPrP(23–231)
showed aggregate clusters of different heights (Tables 1 and S3 and Figs 2B and S3). 3-D views
and height distribution (Fig 2C) revealed structures with different topologies from different
amyloid preparations.
The analyses of both AFM and kinetics data showed that different amyloid preparations in
which pH, denaturing conditions, ionic strength and REDOX processes were defined, reflect
differences in aggregation pathways and morphology of recMoPrP(23–231) end products.
As spontaneous air re-oxidation occurs in the REDOX amyloid preparation process, the
disulfide bonds may rearrange, changing from monomeric intramolecular PrP form to
Fig 1. Aggregation assay of recMoPrP(23–231). Recombinant mouse PrP residues 23–231 (recMoPrP(23–231)) was converted in vitro into different
amyloid forms (amyloids #4, #19, #28, #32). The amyloid preparations shown (A) exhibited different kinetics for the formation of recMoPrP(23–231)
aggregates. Lag phase distribution of amyloid preparations. Bars indicate standard deviation (B).
doi:10.1371/journal.ppat.1005354.g001
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Fig 2. AFM characterization of amyloid fibrils. Atomic Force Microscopy (AFM) imaging analysis was performed at the end of the fibrillization reactions
after 72 hours (amyloids #4, #19, #28, #32). AFM scan topographical images of prion protein (PrP) deposited on mica surface, large-scale images (A). AFM
height profiles along the numbered lines in topographical images. The profile reflects the lines as numbered in the images. Higher resolution scan images
belonging to the area are marked by a white dashed square in part A (B). Three-dimensional representation of AFM topography images and height
distribution data obtained from the AFM images in part B (C).
doi:10.1371/journal.ppat.1005354.g002
Novel synthetic prion
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intermolecular multimeric PrP. In order to prove that the converted amyloid forms under
different amyloid preparations from the REDOX process were oligomerized through intermo-
lecular disulfide bonds, we checked for the presence of these structures. In comparison with
non-reducing experiments, we used a high concentration of reducing agent and reduced elec-
trophoresis. Western blottings showed that converted amyloid forms from both processes had
apparent monomeric, dimeric molecular masses and higher, more complex multimeric forms
under non-reducing treatments (Fig 3A). After treatment with the reducing agents to disrupt
all disulfide bridges, the REDOX-converted PrP forms showed a significant decrease in dimeric
and trimeric structures (Fig 3B, REDOX amyloids). In amyloid preparations established fol-
lowing the REDOX process—which includes the swapping of domains and the rearrangement
of intra and intermolecular disulfide bridges in PrP molecules—the conversions require both
non-covalent and covalent bonds to break up. Moreover, induced reduction occurs optimally
in denaturing condition. Therefore, after incubating the REDOX-converted forms with high
concentration of denaturant (Gdn-HCl 6M) for three days and subsequently treating them
with reducing agent, the amyloid forms were disassembled. This was indicated by the disap-
pearance of PrP complexes with structures other than the monomeric form (Fig 3C, REDOX
amyloids). In contrast, recMoPrP(23–231) converted into the amyloid forms in the non-
REDOX process—in which the oxidized PrP was diluted to reach the final concentrations in
fibrillization buffer—showed greater stability of dimeric and higher structures after treatment
with reducing agent (Fig 3B and 3C, non-REDOX amyloids). Besides the differences in mor-
phology and kinetics formation, our intermolecular disulfide bridge tests showed that REDOX
amyloids are most likely to contain intermolecular disulfide bridge conformation structures
[24, 27, 28]. So far, PK-resistance has been used to distinguish PrPC from PrPSc, although
many studies showed the existence of PK-sensitive PrPSc. We treated amyloid fibrils at PK/
recMoPrP(23–231) ratios of 1:10 and under standard conditions used for detecting PrPSc in
brain homogenates (20 μg/mL PK, at 37°C for 1 hour) at the ratio of 1:1. This process aimed at
determining whether: (i) our abnormal isoforms of PrP generated in vitro are resistant to PK
digestion, and (ii) they have a PK-resistant core resembling that of PrPSc subjected to PK treat-
ment. Both the β-oligomers and the amyloid fibrils in some amyloid preparations showed PK-
resistance. Interestingly, in both processes, most amyloid preparations in Phosphate Buffer
Saline (PBS) pH 7.4 appeared more sensitive to PK digestion than those in acidic conditions,
although digestion patterns were undistinguishable (Figs 4 and S4). At ratio 1:10, the PK-resis-
tant bands of non-REDOX amyloid digestion displayed several resistant fragments with molec-
ular masses in the range of ~17–19 kDa. Only in the case of amyloid preparations in acidic pH,
molecular masses were less than 15 kDa. By contrast, REDOX amyloid fibrils exhibited PK-
resistant bands of molecular masses in the range of ~17–19 kDa (Figs 4 and S4). In particular,
after treatment with PK at ratio 1:1, amyloid fibril #28 showed bands with molecular mass of
~16 kDa (Fig 4). Notably, amyloid preparations subjected to the REDOX process in neutral
buffers (S4 Fig) showed most PK-sensitive structures. Upon treatment with high concentration
of PK, nearly all of these amyloid preparations were almost entirely digested, showing only
Table 1. Different height of clusters of recMoPrP (23–231) aggregates.
Amyloid preparation (#) [Gdn-HCl] (M) Buffer pH Height (nm) Top height distribution (nm)
4 4 50mM Acetate 5.0 1.8–2.2 1.8
19 2 PBS 7.4 25–50 25
28 3 50mM Acetate 5.0 1.2–2.5 2.5
32 1 PBS 7.4 2.5–4.5 4.5
doi:10.1371/journal.ppat.1005354.t001
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Fig 3. Western blot analysis of amyloid fibrils performed under reducing and non-reducing SDS-PAGE.Monomeric (indicated by blue arrow)
recMoPrP(23–231) was converted into amyloid forms by intermolecular disulfide linkage following the REDOX process. Western blotting of non-reducing
Sodium Dodecyl Sulphate—PolyAcrylamide Gel Electrophoresis (SDS-PAGE) showing the conversion of recMoPrP(23–231) to amyloids is indicated by
dimer (green arrow), trimer (red arrow), and more complex structures in both processes (A). Western blotting of reducing SDS-PAGE after treatment of
amyloid with Dithiothreitol reducing agent (DTT) shows the decrease in signals of dimer, trimer and more complicated structures in all lanes of amyloid
samples from REDOX-process (B). Western blotting of reducing SDS-PAGE of amyloid after a 3-day treatment with denaturant (6M Gdn-HCl), and
subsequently with reducing agent DTT shows only monomeric recMoPrP(23–231) bands and the disappearance of more complicated structures in all lanes
of amyloid samples in REDOX process (C). Western blots were performed using Fab D18 monoclonal antibody (1μg/mL). Blots were developed with the
enhanced chemiluminescent system (ECL, Amersham Biosciences) and visualized on Hyperfilm (Amersham Biosciences)
doi:10.1371/journal.ppat.1005354.g003
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trace amounts of similar kDa bands. The biochemical analyses of our amyloid preparations
showed that in different biochemical and biophysical environments, recMoPrP(23–231) con-
verted to distinct amyloidal forms. These different structures exhibited distinct stability in the
presence of high concentration of denaturant (Fig 3C), PK treatment (Figs 4 and S4) and
molecular masses patterning of PK-resistant cores. Kinetic studies of fibrillization (S2 Fig)
showed that at neutral pH, the lag phase of recMoPrP(23–231) was short, and the protein was
more prone to generate amyloids different from those formed at different pH. Interestingly,
the stability of amyloid forms under neutral pH condition was lower.
The molecular basis of prion infectivity is the ability of PrPSc to efficiently induce the con-
version of PrPC into PrPSc. This process follows the seeding-nucleation model, with infectious
PrPSc acting as a seed to capture PrPC into a prion polymer [35].
Seeding ability in cell cultures
Using cell-cultured models for the screening of several amyloid preparations, we seeded our
amyloid fibrils to cultured mouse hypothalamic GT1, mouse neuroblastoma N2a cells and
mouse hippocampal knockout PrP HpL3-4 cells [36]. After six cell passages, mildly PK-resis-
tant PrP (Figs 5A and S5) and aggregated forms of PrP were found in amyloid fibril-infected
GT1 as well as in N2a cells (Figs 5B, S6 and S7), whereas HpL3-4 knockout PrP cells did not
harbor any detectable aggregated PrP. Throughout serial passages, endogenous PrPC was
induced to change its conformation to mildly PK-resistant PrP forms, which were maintained
after passages (Fig 6).
Some preparations induced aggregation only in one cell line (S5, S6 and S7 Figs). Notably,
different batches of the same amyloid, prepared at different times, were characterized by simi-
lar PK resistance and infectious properties, either in cell lines and by means of PMCA (S12
Fig). Cell lines used in this work derived from different sources, which may account for the
diverse susceptibility to various conformations of putatively infectious PrP. Interestingly, incu-
bation with some amyloid preparations did not promote PK-resistant PrP formation in either
GT1 or N2a cells (Figs 5A and S5).
Fig 4. PK digestion assay of amyloid #4, #19, #28 and #32.Western blotting of PK digestion assay
(amyloids #4, #19, #28, #32) showed partial protease K (PK) resistance of recMoPrP(23–231) (amyloids #4
and #28). RecMoPrP(23–231) amyloids (PK- lanes) were digested with PK at ratio 1:10 (w/w) (PK+ lanes)
and 1:1 (w/w) (PK++ lanes). Western blots were performed using Fab D18 monoclonal antibody (1μg/mL).
Blots were developed with the enhanced chemiluminescent system (ECL, Amersham Biosciences) and
visualized on Hyperfilm (Amersham Biosciences)
doi:10.1371/journal.ppat.1005354.g004
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The immunofluorescence analyses of amyloid fibril-infected cell lines (Fig 5B) showed dif-
ferent staining and stronger PrP immunoreactivity detection than those of uninfected cells in
both N2a (S6 Fig) and GT1 (S7 Fig) cell lines. Some cells showed accumulation, indicated by
punctates and clusters of immune signal. Detected PrP accumulation in amyloid fibril-infected
cells was found at the cell membrane and in the cytosolic compartments.
These data suggested that amyloid preparations, in both REDOX and non-REDOX condi-
tions, can act as seeds, like natural prions do, in propagating within cultured neuronal cells,
leading to accumulation and promotion of PK-resistant PrP forms from endogenous PrP.
In several recent independent studies on different proteins, both synthetic and natural amy-
loid forms have been shown to induce apoptosis in cell cultures [37–39] thus suggesting that
these amyloids might be toxic. To check for possible toxic effects on our neuronal cell lines, we
Fig 5. Seeding assay of N2a and GT1 cell cultures with synthetic amyloid fibrils. Seeding of recMoPrP(23–231) amyloid preparations induced the
conversion of endogenous PrPC to mildly PK resistant forms (A) and accumulation (B) in mouse neuroblastoma N2a and mouse hypothalamic GT1 amyloid-
infected cell lines analyzed six passages after the infection (P6). Western blotting shows the partial protease K (PK) resistance of N2a and GT1 amyloid fibril-
infected cell lysates. Fibril-infected cell lysates (PK-lanes) were digested with PK at ratio 1:500 (w/w) (PK+ lanes). Western blots were performed using Fab
D18 monoclonal antibody (1μg/mL) for GT1 infected cells and Clone-P (1μg/mL) for N2a infected cells. Blots were developed with the enhanced
chemiluminescent system (ECL, Amersham Biosciences) and visualized on Hyperfilm (Amersham Biosciences) (A). Immunofluorescence imaging shows
the accumulations of PrP in N2a and GT1 amyloid fibril-infected cell lines. The deposition and level of PrP (green) in amyloid fibril-infected cell lines after six
passages were detected by Fab D18 monoclonal antibody (10 μg/mL final concentration). The nuclei (blue) were stained with DAPI. Scale bar is 20μm (B).
doi:10.1371/journal.ppat.1005354.g005
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measured cell viability after treatment with amyloid preparations in a similar procedure with
amyloid fibril-infected cell assay using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetra-
zolium Bromide) assay. Indeed, some amyloid preparations showed toxicity in cell culture
while most did not (S8 Fig).
PMCA propagation and infectivity in wild-type animals
Two of the amyloid preparations described in this manuscript, amyloid #4 and #28, were fur-
ther analyzed by different techniques. Particularly, we assessed their ability to propagate in
vitro by means of PMCA using the brain of CD1 mice as substrate for amplification. Only the
preparation #4 showed a PK resistant PrP (PrPRes) signal after three rounds of PMCA while
preparation #28 did not (Fig 7). Similarly, the cell lysates obtained from both N2a and GT1
cells infected with amyloid preparations #4 or #28 (collected at passage 6) were used as seed for
PMCA reaction. The lysates of both cell lines infected with amyloid #4 were able to amplify in
PMCA harboring a PK resistant signal after 3 rounds of amplification while preparation #28
was not able to amplify (Fig 7). Similar results were obtained in PMCA experiments performed
using new batches of raw fibrils or lysates from cells infected with different preparations of the
same amyloid (S12E Fig). Remarkably, the glycoform ratio of the amplified product derived
from amyloid #4 (either from crude amyloid or from cell lysates) was always characterized by a
prevalence of the diglycosylated band after PK digestion. The unglycosylated form of PrPRes
migrated at around 20 kDa (Fig 7). Finally, both amyloid preparations were intracerebrally
inoculated in CD1 mice. A group of animals were injected with normal PBS as control. None
of the animals injected with amyloid preparations showed any prion pathology and were culled
at the end of their lifespan (720 days post injection). Immunohistochemical (S10A Fig) and
biochemical (S10B Fig) analysis confirmed the lack of spongiosis, PrPRes deposition and astro-
glial or microglial activation [40]. The presence of trace amounts of synthetic prion preparation
Fig 6. PK digestion assay of GT1 and N2a cells collected at different passages after infection with amyloid fibrils.Western blotting of GT1 and N2a
cell lines infected with PrP amyloid #4 was observed throughout, from first passage (P1) to sixth passage (P6) and after treatment with proteinase K at ratio
1:500 (w/w). Western blot was performed using Fab D18 monoclonal antibody (1μg/mL). Blots were developed with the enhanced chemiluminescent system
(ECL, Amersham Biosciences) and visualized on Hyperfilm (Amersham Biosciences).
doi:10.1371/journal.ppat.1005354.g006
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in the brain of these animals was analyzed by means of PMCA. In accordance with the in vitro
results, only the animals injected with preparation #4 showed the presence of a PrPRes signal
after 2 rounds of PMCA while we could not detect any signal when analyzing the brain of
the animals injected with preparation #28 (Fig 8A). The PrPRes amplified in preparation #4
(PMCA-#4) was biochemically analyzed and compared with known prion strains: (i) mouse
adapted-variant CJD (vCJD), (ii) RML and (iii) ME7. We noticed that the unglycosylated band
of PMCA-#4 migrated at around 20 kDa, in an intermediate position compared with the one
of RML or ME7 and the one of mouse adapted-vCJD (Fig 8B). These results were confirmed
with Peptide-N-Glycosidase (PNGase) experiment (Fig 8C). The higher molecular weight (20
kDa) of the unglycosylated band of PMCA-#4 compared to the one of the synthetic prepara-
tion (17–19 kDa) might be explain by the presence of the GPI anchor which is added in vivo.
With this experiment we could also rule out the possibility that the signal obtained in PMCA-
#4 could have derived from PMCA contamination with Bovine Spongiform Encephalopathy
(BSE) or vCJD (known to have a prevalence of the diglycosylated form of PrPRes).
We performed two different transmission studies. In the first one, two groups of CD1 mice
(n = 10) were intracerebrally injected with 10% brain homogenate obtained either from the ani-
mal injected with preparations #4 or PBS. In the second transmission study, we wanted to
assess whether PMCA-#4 possessed infectious properties. In this case two groups of 10 animals
were intracerebrally injected with either PMCA-#4 or PMCA-PBS. At the time of writing, no
animals of the first study injected with preparation #4 show clinical signs of disease (430 days
post inoculation). All animals of the second study injected with PMCA-#4 showed an incuba-
tion and survival time of 130 ± 4 and 160 ± 3.85 days (mean ± Standard Error of the Mean,
SEM) (Fig 9). The brains of two terminally sick animals from this group were collected and
used for biochemical and immunohistochemical analysis. As shown in Fig 10A the animals
Fig 7. PMCA analysis of raw fibrils and cell lysates from infected N2a and GT1 cell lines. Seeding ability of amyloid #4 and #28 by means of PMCA
using brain homogenates of CD1 mice as substrates for amplification (A). PMCA analysis of GT1 and N2a cell lysates (infected with preparations #4 and #28)
and collected at passage six (P6) after the infection (B). Black arrow indicates PK-resistant PrP. Asterisk indicates unspecific binding. Western blots were
performed using 6D11 monoclonal antibody to PrP (0.2 μg/mL, Covance). Blots were developed with the enhanced chemiluminescent system (ECL,
Amersham Biosciences) and visualized using a G:BOX Chemi Syngene System.
doi:10.1371/journal.ppat.1005354.g007
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showed widespread PrPRes deposition, prevalently affecting the hippocampus, thalamus and
striatum with plaque-like deposits mainly observed in the submeningeal region of the cerebral
cortex and occasionally found in the striatum (Fig 10A). Thioflavin-S (ThS) staining revealed
that these deposits did not possess the amyloid tintorial properties (Fig 10B). RML injected
mice showed typical synaptic and diffuse PrPRes deposition without the presence of plaque-like
deposits that were observed in PMCA-#4 injected animals. Severe spongiform changes were
detected in the hippocampus and dorsal medulla of PMCA-#4 infected animals (Figs 10B and
9C) while few vacuoles were found in the rest of the brain, including cerebral cortex and cere-
bellum (Figs 10A and 9C). On the contrary, RML injected mice showed the highest spongiform
changes in the thalamus, septum and cerebral cortex (Fig 9D). Biochemical analysis showed
Fig 8. Amplification and characterization of a new prion isolate obtained from the brain of amyloid-infected animals. PMCA assessment using the
brain homogenate of injected animals (with amyloid #4 or #28) as seed and the brain of wild type CD1 animals as substrate. Serial dilution of RML prion strain
were used as internal control for PMCA efficiency (A). Western blot (B) and PNGase comparison (C) of amplified clone #4 (PMCA-#4) with known prion
strains (RML, mouse adapted vCJD and ME7). Read arrows in B and C indicate the different electrophoretic mobility of the unglycosylated PrP band of
PMCA-#4 (migrating at around 20kDa) compared to that of known prion strains migrating at 19 kDa or 21 kDa (black arrows). Western blots were performed
using 6D11 monoclonal antibody to PrP (0.2 μg/mL, Covance). Blots were developed with the enhanced chemiluminescent system (ECL, Amersham
Biosciences) and visualized using a G:BOX Chemi Syngene system.
doi:10.1371/journal.ppat.1005354.g008
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the presence of a PK resistant PrP with a glycoform profile similar to that of the inoculum
(PMCA-#4) and characterized by a prevalence of the diglycosylated band (Fig 10C). RML
injected mice were characterized by the presence of a typical PrPRes characterized by a predom-
inant monoglycosylated band (Fig 10D). The blood of a PMCA-#4 symptomatic animal, col-
lected at 140 days post infection, was analyzed by means of PMCA and showed the presence of
a PK-resistant PrP in the second round of amplification which was characterized by a preva-
lence of the diglycosylated band (Fig 10C). Using the RML as positive control for PMCA, we
could estimate that the concentration of infectious prion circulating in blood is similar to that
of a 10−10/10−11 dilution of brain homogenate.
Discussion
The production of synthetic prions was introduced in 2004, via a simple in vitro induction of
misfolding and aggregation of bacterially expressed recPrP [15]. PrP amyloids possessing
Fig 9. Incubation time, survival time and lesion profile analysis of PMCA-#4 infected animals. The animals injected with PMCA-#4 showed an
incubation (A) and survival time (B) of 130 ± 4.4 and 160 ± 3.85 days (Mean ± Standard Error of the Mean, SEM) and results were analyzed with the Logrank
test. Spongiform profiles were determined on Hematoxylin and Eosin (H&E)-stained sections, by scoring the vacuolar changes in nine standard gray matter
areas: 1. Dorsal medulla; 2. Cerebellar cortex; 3. Superior culliculus; 4. Hypothalamus; 5. Thalamus; 6. Hippocampus; 7. Septum; 8. Retrosplenial and
adjacent motor cortex; 9. Cingulated and adjacent motor cortex, as described by Fraser et al. [54]. Lesion profile was compared to that of RML (i.c.) infected
animals. Bars in C and D indicate Standard Error of the Mean.
doi:10.1371/journal.ppat.1005354.g009
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different conformation stability were generated by altering the conditions for their formation,
including urea concentration, pH and temperature. After passaging in mice, a large ensemble
of synthetic prions showed a direct relationship between stability and incubation time of novel
prion strains [6]. The recent, impressive progress in this technique has spurred the renewed
investigation of prion structural biology [41–45].
The aggregation pathway plays an important role in prion disease as it is commonly
accepted that both species barrier and strain phenomenon are due to different conversion
Fig 10. Detection of PMCA-#4 in brain and blood of infected animals and related immunohistochemical/biochemical characterization.
Neuropathological analysis of PMCA-#4 and PMCA-PBS injected animals and comparison to that of RML infected mice. Animals injected with PMCA-#4
showed widespread deposition of PrPRes in the hippocampus with focal plaque-like deposits found in the cerebral cortex. Cerebellum is completely spared by
PrPRes accumulation. RML injected animals showed the typical pattern of widespread, synaptic and diffuse PrPRes accumulation in the whole brain with
major involvement of thalamus and hippocampus. Spongiform changes were mainly found in the hippocampus of PMCA-#4 injected animals. Few vacuoles
were detected in the cerebral cortex, while cerebellum did not show any vacuolation. RML injected animals showed severe vacuolation in the thalamus and
hippocampus. Mild alterations were found in cerebellum and septum. Brain of PMCA-PBS injected animal was used as control (A). Higher magnification of
the red square in panel A (see asterisk) and Thioflavin-S staining showing the lack of amyloid properties of the deposits found in the submeningeal level of
the cerebral cortex (B). PMCA of blood collected at 140 day post infection (d.p.i.) from a symptomatic animal injected with PMCA-#4. RML dilutions (10−10
and 10−11) were used in PMCA to estimate the concentration of circulating infectious PrP (C). Biochemical analysis of the brains harvested from the first two
animals injected with PMCA-#4 (sacrificed at terminal stage of the disease) were performed and compared to that of RML injected mice (D). Scale bar in A is
10 μm; scale bar in B is 5 μm.Western blots were performed using 6D11 monoclonal antibody to PrP (0.2 μg/mL, Covance). Blots were developed with the
enhanced chemiluminescent system (ECL, Amersham Biosciences) and visualized using a G:BOX Chemi Syngene system.
doi:10.1371/journal.ppat.1005354.g010
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pathways [46]. However, the molecular basis of prion conversion remains unclear, especially
the varied structural landscape of PrPSc, which forms the basis of the strain phenomenon [47].
Therefore, the differences in conformational amyloid states of putative infectious materials—
which can be generated in vitro under defined biophysical and biochemical conditions using
recPrP—are the key elements to determine the biological activities of functional, pathological
amyloid fibrils. In our studies, we created amyloid fibers under an array of different chaotropic
conditions at two pH values: either mimicking the extracellular environment (neutral pH) or
the endocytic compartment (acidic pH at 5). Although the high concentrations of chaotropic
agent are not close to physiological conditions, in these cases the kinetics of full-length PrP
showed the tendency of the protein to adopt different folding states, which may encipher alter-
native pathogenic states (so-called prion states). In the presence of Gdn-HCl, our data showed
a direct correlation between protein concentration and the final morphologies in fibrillizations
(S3B Fig).
Although most fibrillizations were obtained in 72 hours and the stable kinetics of some
amyloid preparations was long, the final samples of some fibrillizations visualized under AFM
showed oligomeric morphologies (Figs 2 and S3A). Indeed, several oligomerization pathways
of PrP may coexist, underlying that some oligomeric types may eventually assemble into fibrils,
whereas others may just lead to a dead-end pathway [48, 49].
Earlier works reported that, in infected brains, PrPSc accumulates at the plasma membrane
and occasionally in late endosome/lysosome-like structures [50]. More recent studies show
that prion conversion occurs in the endosomal recycling compartment where it transits after
being internalized from the cell surface [51]. In addition, in both REDOX and non-REDOX
processes, under similar concentration of denaturant and ionic strength, at either neutral pH
or acidic pH, a shorter lag phase (S2 Fig) indicated that recMoPrP(23–231) is prone to convert
to amyloid forms under neutral pH. On the other hand, amyloid fibrils converted in neutral
pH showed low stability when treated with protease and denaturant. In fact, studies have
showed that, in mice, less stable amyloids produced less stable prion strains, exhibiting short
incubation time [6]. Generally, they replicate faster because of the lower stability. These data
suggested that the very first step for PrP conversion and spreading may occur at extracellular
sites. Tanaka et al. showed that infection of yeast with different amyloid conformations com-
posed of a recombinant Sup35 fragment leads to different [PSI+] strains. This evidence indi-
cates that this prion protein adopts an infectious conformation before entering the cells [10].
In general, prion diseases are known to be triggered by PrP conformational conversion and
subsequent aggregation [52]. These aggregates may be determined by non-covalent hydropho-
bic interactions and/or intermolecular disulfide bond formation. The oxidized and reduced
states are two basic states of PrP, which are responsible for the formation of disulfide bonds.
Starting from these two states, our amyloid preparation processes revealed different formation
mechanisms. In the non-REDOX process, the oxidized recMoPrP at high concentration of
denaturant was diluted directly into the fibrillization buffer in order to reach the final concen-
trations. During this procedure, protein particles seem to take a random pathway and aggre-
gate. In this case the size of the clustered aggregation sometimes can be larger than those held
together by regular, weaker forces, and may thus cause precipitation [53]. The underlying
kinetic mechanism is likely to be a diffusion-limited aggregation process [54]. Indeed, at 3M
Gdn-HCl at non-REDOX condition after 72 hours of 15-minutes interval shaking (S9 Fig), we
achieved a classical form of diffusion-limited aggregation, whereas this was not obtained for
condition #28 (REDOX).
Despite sharing the same conversion mechanism based on domain swapping and rearrange-
ment of disulfide bridge, our REDOX amyloid preparation process differs from one previously
described [24] in which His-tag hamster PrP(90–231) was converted into oligomeric forms
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and showed seed conversion properties in cell-free conversion systems. Indeed, in some cases
our REDOX amyloid preparations exhibited a PK-resistant PrP band with a molecular mass of
~19 kDa, as well as characteristics similar to amyloid preparations obtained using a non-
REDOX process. These results depart from data reported by Lee S. et al [24].
Considering all these data, it seems that the amyloid fibril prepared under non-REDOX
condition (#4) is more prone to coerce the misfolding of PrPC when assessed either in vitro or
in vivo. Notably, the glycoform ratio of this amyloid was tightly maintained in PMCA that was
seeded with different source of infectious preparation: (i) raw fibrils preparation, (ii) N2a or
GT1 infected cell lysate, (iii) brain homogenate of infected animals. In fact, a vCJD-like glyco-
form ratio, with a predominance of the diglycosylated band of PrP was always observed. This
might be a potential pitfall of the amplification procedure when using a synthetic material,
which does not possess an intrinsic original glycosylation pattern. In fact, it has been widely
reported that PMCA maintains the biological and infectious properties of the prion strain used
as inoculum. In this case, the glycosylation profile of PMCA-#4 might reflect the normal glyco-
sylation pattern of PrPC that was used as substrate for amplification (S11 Fig). When injected
in animals, amyloid #4 and #28 did not produce any evident prion pathology. Thus, we have
analyzed the CNS of these animals by means of PMCA. After two rounds of PMCA we could
detect the presence of a PK-resistant PrP in the brain of a mouse injected with the preparation
#4, while we have never detected any PK-resistant protein in the brain of the animals injected
with preparation #28 (even after 6 round of PMCA). In this case, we cannot rule out the pres-
ence of infectious material in the CNS of mice inoculated with preparation #28 since it could
be a new PK-sensitive prion isolate that we cannot detect with our analytic techniques based
on PK treatment of the samples.
Here we show that seeds derived from our recMoPrP(23–231) amyloid fibrils, which were
generated by an array of recMoPrP(23–231) amyloid preparations, exhibited different struc-
tural properties due to different mechanisms of prion aggregation. When directly added to
neuronal cell lines, endogenous PrPC was induced to change its conformation to PK-resistant
PrP forms, which are well-known diagnostic markers for prions. We used immunofluorescence
with confocal microscopy to show location and level of PrP within the neuronal amyloid fibril-
infected cells at sixth passage. This observation suggested that small amounts of amyloid fibrils,
which were added only in the beginning passage (P1), could seed endogenous misfolded PrP
and lead it to accumulate at membrane and cytosolic compartments. Therefore, our amyloid-
infected cell culture assay using recMoPrP(23–231) to produce synthetic prions may facilitate
investigation aimed at unraveling mechanistic steps in prion formation. This method is indeed
a useful and time-efficient tool for screening putative infectious materials.
Infection of wild type animals with amyloid #4 (either first and second passage) did not pro-
duce any clinical sign of prion disease. This phenomenon could have several explanations. For
example, Makarava et al. [55] reported that there is a period of time where the fibrillar rPrP
structure is converted to an intermediate and atypical form of PrPRes (deformed templating)
before producing the classical PrPSc which is able to trigger evident pathological changes in
mice. Since the atypical PrPRes is characterized by a short PK-resistant core, a preference for a
monoglycosylated PrP and inactivity in PMCA, we have digested the brain of mice injected
with amyloid #4 and #28 (first passage) with different concentrations of PK and used anti PrP
antibodies which recognize more C-terminal fragments of PrP (SAF-84, residues 160–170;
SAF-61 and W226 antibodies which recognize residues 144–152). Even with these modifica-
tions we could never detect any typical or atypical PK resistant PrP. Another explanation for
the lack of pathological changes in mice injected with amyloid #4 and #28 could be attributable
to the small amount of infectious material used to challenge the animals. In this case, the
amount of amyloids could not have been sufficient to misfold enough PrPC and induce
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neuropathological or clinical alterations. This point is supported by our PMCA experiments
where we observed that the brain of mice injected with amyloid #4 (first passage) culled at the
end of their life-span showed a PrPRes signal after 3 rounds of amplification. When injected in
wild type mice, this amplified product (PMCA-#4) was found to be highly aggressive with an
attack rate of 100%. In particular, incubation and survival time were 130 ± 4.4 and 160 ± 3.85
days (mean ± standard error of the mean), respectively. The analysis of brains collected from
two animals confirmed the presence of PK resistant PrP with distinctive biochemical and
neuropathological features. Specifically, the PrPRes showed an uncommon migration profile
(compared to known prion strains) with a prevalence of the di-glycosylated band. Neuropatho-
logical analysis revealed a synaptic pattern of PrP deposition with few focal deposits (confined
to the submeningeal level of the cortex) negative for ThS staining. Finally, this PK-resistant
PrP was detected in blood (plasma fraction) collected at 140 days post injection thus demon-
strating the aggressiveness of the new prion isolate.
The data we gathered lead us to four important conclusions. Firstly, putative infectious
materials can be generated in vitro, under controlled and well-defined biophysical and bio-
chemical conditions using solely recPrP and some simple chemicals, without employing prion-
infected brain homogenate or purified PrPSc. Secondly, the PK-resistant ability of amyloid
fibril-infected cells was maintained during cellular passages. Thirdly, different structural prop-
erties of putative infectious materials may account for different prion characteristics. Fourthly,
we observed that the amyloid preparation produced in vitro (#4) maintained the same bio-
chemical profile when amplified directly from (i) the synthetic preparation or (ii) the infected
cell lysates and finally (iii) from the brain of infected mouse. Overall, the production of differ-
ent batches of the amyloid (#4) maintained the same biochemical and infectious properties
when inoculated in cells and challenged by means of PMCA. Nevertheless, after PMCA ampli-
fication, this newly generated synthetic prion was found to induce a severe prion pathology
when injected in mice thus confirming that the synthetic material is stable and infectious.
Materials and Methods
Ethics statement
Mice were housed in groups of 2–5 animals in individually ventilated cages, daily fed and water
provided ad libitum. Lighting was on an automatic 12 h basis. Regular veterinary care was daily
performed for assessment of animal health. Animal facility is licensed and inspected by the Ital-
ian Ministry of Health. Current animal husbandry and housing practices comply with the
Council of Europe Convention ETS123 (European Convention for the Protection of Vertebrate
Animals used for Experimental and Other Scientific Purposes; Strasbourg, 18.03.1986); Italian
Legislative Decree 26/2014, Gazzetta Ufficiale della Repubblica Italiana, 26 July 2014; and with
the 86/609/EEC (Council Directive of 24 November 1986 on the approximation of laws, regula-
tions and administrative provisions of the Member States regarding the protection of animals
used for experimental and other scientific purposes).
The study, including its Ethics aspects, was approved by the Italian Ministry of Health (Per-
mit Number: NP-02–14). All surgery was performed under tribromoethanol anesthesia, and all
efforts were made to minimize suffering.
Expression and purification of recPrP
RecMoPrP(23–231) was expressed in E. coli Rosetta2(DE3) with pET11a(MoPrP23-231)-with-
out His-tag. The transformed bacteria were grown in Luria Bertani (LB) media using a Biostat
B plus fermenter 2L vessel. Expression was induced with Isopropyl β-D-1-thiogalactopyrano-
side (IPTG) at a final concentration of 1mM. The cultures were harvested after 24 hours of
Novel synthetic prion
PLOS Pathogens | DOI:10.1371/journal.ppat.1005354 December 31, 2015 18 / 28
induction, centrifuged (1500 x g, 30min, 4°C) and resuspended in buffer A (25mMTris-HCl
pH 8.0, 5mM Ethylenediaminetetraacetic acid (EDTA), 1mM phenylmethylsulfonyl fluoride
(PMFS)). After centrifugation, pellets were resuspended in buffer B (25mMTris-HCl, 5mM
EDTA, 1mM PMSF, 0.5% Triton X-100). To disrupt bacterial cells, the solution was passed
three times through the microfluidizer at 15000–18000 psi. The solution was centrifuged for
30min at 3400 x g and inclusion bodies were washed twice with buffer C (25mMTris-HCl,
5mM EDTA, 0.8% Triton X-100) and buffer D (25mMTris-HCl pH 8.0) and twice with dou-
ble-distilled H2O. Pellets containing MoPrP(23–231) protein were solubilized in 8M Gdn-HCl,
shaken overnight at 37°C and centrifuged (3400 x g, 30min). The solution was then brought to
buffer containing 6M Gdn-HCl, 20mMTris-HCl pH8.0, 500mMNaCl and loaded onto
HisTrap FF crude column (GE Healthcare). The column was washed with buffer A (20mM
Tris-HCl pH 8.0, 10mM Imidazole, 2M Gdn-HCl) and protein was eluted with linear imidaz-
ole gradient (20–500 mM imidazole in buffer A). Fractions containing MoPrP(23–231) protein
were then loaded onto reverse phase column (Jupiter C4, 250x21.2mm, 300 A, Phenomenex).
The column was washed with buffer A (0.1%TFA) and protein was eluted with a linear gradient
from 0 to 95% acetonitrile in 0.1% Trifluoroacetic Acid (TFA) (buffer B). Samples containing
PrP protein were then lyophilized.
Amyloid preparations
RecMoPrP(23–231) was expressed and purified as described. All stock solutions for fibrilliza-
tion were sterile, filtered through a 0.22μm filter prior to each assay in order to avoid the pres-
ence of contaminants. Lyophilized protein was dissolved in 6M Gdn-HCl at 10mg/mL or 8M
Urea at 10mg/mL, aliquoted, and frozen at -80°C. To form fibrils in the non-REDOX process,
a solution of Gdn-HCl (concentrations are indicated in Table 1), 50mM buffer acetate pH 5.5
or PBS pH 7.5, NaCl (concentrations are indicated in S1 Table) and 10 μm Thioflavine T
(ThT) was mixed before adding recPrP, which has a final concentration of 100 μg/mL or
200 μg/mL (indicated in S1 and S2 Tables). To form fibrils in the REDOX process as described
(Fig 1), after dissolving in 6M Gdn-HCl, the lyophilized protein was reduced by adding
100mMDithiothreitol (DTT) at 37°C for 1 hour. In case of conditions containing NaCl (as
indicated in S2 Table) this was added to the protein stock solution saturated level. The next
steps were the same as those of the non-REDOX process described above. For fibrillization, a
3-mm glass bead (Sigma) was added to each well of a 96-well black plate with clear bottom (BD
Falcon). The final volume protein solutions were added to 200 μL/well. The plate was covered
with sealing tape (Fisher Scientific) and shaken continuously at 37°C using M5 fluorescence
plate reader with automix capability (Spectramax M5 Molecular Devices. ThT fluorescence
was measured with the same plate reader at 444/485 nm excitation/emission spectra every 5
min after 72 hours or 52 hours continuous shaking by bottom fluorescence reading. Each sam-
ple was measured in six independent replicate wells. Fibrils were collected by ultracentrifuga-
tion at 100,000 x g for 30 min to remove other soluble components before further
characterizations.
Atomic force microscopy (AFM)
This method was employed in accordance with that described above [31, 56]. Specimen were
imaged with a Nanowirzard-II BioAFM (JPK Instruments AG, Berlin, Germany, www.jpk.
com) operating in dynamic mode and using non-contact Si cantilevers (NSG11, NT-MDT–
Moscow, Russia, www.ntmdt.com or ARROW-NCR, Nano World-Neuchȃtel, Switzerland,
www.nanoworld.com) with tip radii of<7–10 nm, spring constants of 20–40 N/m, and reso-
nance frequencies of 285–325 kHz. After fibrillization, 5–10μL samples were spread onto a
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freshly cleaved mica sheet and left to adhere for 10-20min. Samples were then washed with dis-
tilled H2O and dried naturally. The images were acquired at line scan rates of 0.5–1 Hz at room
temperature (RT). The AFM free oscillation amplitudes ranged from 25nm to 40nm, with
characteristic set points ranging from 75% to 90%. AFM data were analyzed with Gwyddion
(www.gwyddion.net).
Testing for disulfide bond interchain of fibrils from REDOX process
After fibrillizations, 1μg of protein samples was precipitated by ultracentrifugation at 100,000 x g
for 30min, dissolved in non-reducing sample buffer (125 mMTrisHCl, pH 6.8, 4% SDS, 0.2%
bromophenol blue, 20% glycerol) and separated in 10% non-reducing SDS-PAGE gels. For disul-
fide bond interchain test, 1μg of protein after precipitation by ultracentrifugation was treated
with (DTT) at the last concentration of 150mM or incubated in 1mL 6MGnd-HCl for 3 days,
then treated with 150mMDTT. These samples were centrifuged at 100,000 x g for 1 hour, resus-
pended in reducing loading buffer, boiled for 10min at 100°C and separated in 10% polyacryl-
amide gels. Western blotting was carried out and gels were subsequently transferred overnight
onto Immobilon P PVDFmembranes (Millipore). Membranes were blocked by 5% non-fat milk,
incubated first with 1 μg/mL anti-PrP Fab D18 and then with goat anti-human IgG F(ab)2 frag-
ment conjugated with horseradish peroxidase (HRP). Blots were developed with the enhanced
chemiluminescent system (ECL, Amersham Biosciences) and visualized on Hyperfilm (Amer-
sham Biosciences).
Preparations of prion amyloid fibrils for cellular assays
Collection of amyloid fibrils from 96-well plates into 1.5 mL tubes was performed under sterile
conditions. Samples were centrifuged at 100,000 x g for 30 min at 4°C in an ultracentrifuge
(Beckman Coulter). The pellets were resuspended in sterile PBS and then sonicated for 5 min
prior to being added to cultured cell media.
Cell cultures
Mouse neuroblastoma N2a cells were cultured in minimal essential medium with Earle’s
salt (EMEM) supplemented with 10% FBS, 1% non-essential amino acids, 1% L-glutamax,
100 units/mL penicillin and 100 μg/mL streptomycin. Mouse hypothalamic GT1 cells and
mouse hippocampal PrP-deficient HpL3-4 were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin
and 100 μg/mL streptomycin. Cell cultures were cultivated in 10-cm plates and incubated at
37°C in humidified 5% CO2. Cells were split at ratio 1:10 for further cultivation when the con-
fluence reached 95%.
Infecting N2a, GT1 and HpL 3–4 cell lines with amyloid fibrils
At the end of the fibrillization, after collection as describe above, 200μL of fibril solutions were
resuspended in sterile PBS and sonicated in a water-cooled cup-horn sonicator for 5min for
preparation of fibrillar infections. Cells were seeded in tissue culture plates 1 day prior to infec-
tion and around 5% confluent on the day of the infection. After removing the media, cells were
washed and changed once with fresh media. After adding fibrils into the media of cells, the
incubation was done over 6-7days. Once confluency was reached, cells in the plate were washed
with PBS, trypsinized and transferred to another tissue culture plate. Cells were subjected to
1:10 split, which was counted as passage 1. Subsequently, cells were subjected to routine cell
culture procedures for further passages. Cell lysates were collected at every passage. After the
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cell plates reached the confluency, they were washed with PBS and lysed in 500 μL cell lysis
buffer (10mMTrisHCl pH 8.0, 150mMNaCl, 5.0% NP40, 5.0% deoxycholic acid sodium salt
(DOC)). Total protein content of cell lysates was measured using bicinchoninic acid (BCA)
protein quantification kit (Pierce) and stored at -20°C until analysis.
PK-resistant PrP detection in amyloid fibril-infected cell lysates by
western blotting
Fibril-infected cell lysates were collected at each passage. The accumulation of PK-resistant
PrP was detected by proteinase K (PK) digestion followed by immunoblotting of lysated cells.
Five hundred μL of lysis buffer (10 mM Tris-HCl pH 8.0, 150 mMNaCl, 0.5%, NP40, 0.5%
DOC) was added to each 10-cm cell plate and cell lysates were collected after centrifugation at
400 x g for 5 min in a bench microfuge (Eppendorf). The total protein content of samples was
measured by means of bicinchoninic acid assay (BCA) (Pierce). Cell lysated samples were
adjusted to 1mg/mL total protein; 2μg/mL PK (Invitrogen) was added to reach the final volume
of 0.5 mL. Following 1 hour incubation at 37°C, digestion was stopped by adding PMSF at 2mM
final concentration. Digestion products were precipitated by centrifugation at 100,000 x g for
1 hour at 4°C in an ultracentrifuge (Beckman Coulter), and resuspended in 2X SDS-PAGE load-
ing buffer (125 mM TrisHCl, pH 6.8, 10% 2-mercapethanol, 4% SDS, 0.2% bromophenol blue,
20% glycerol). For non-PK digested samples, 50 μg of cell lysates were used and 2X SDS-PAGE
loading buffer was added in a 1:1 ratio. The samples were boiled for 10 min at 100°C, loaded
onto a 12% Tris-Glycine SDS-PAGE gel, and transferred overnight onto Immobilon P PVDF
membranes (Millipore). Membranes were blocked by 5% non-fat milk, incubated first with
1 μg/mL anti-PrP Fab D18, Clone P and then with goat anti-human IgG F(ab)2 fragment HRP-
conjugated. Blots were developed with the enhanced chemiluminescent system (ECL, Amersham
Biosciences) and visualized on Hyperfilm (Amersham Biosciences).
PK-resistant PrP detection in different amyloid preparations by western
blotting
After fibrillization, 100 μL samples were centrifuged at 100,000 x g for 30 min at 4°C (Beckman
Coulter ultracentrifuge). Pellets were resuspended in the same volume of PBS. The samples
were then digested by adding either 2 μg/mL or 20 μg/mL of PK in PBS for 1 hour at 37°C. The
reaction was stopped with 2 mM PMSF and the PK-digested samples were centrifuged at
100,000 x g for 1 hour at 4°C (Beckman Coulter ultracentrifuge). Pellets were resuspended in
1X SDS-PAGE loading buffer. The non-PK digested samples of fibril solutions were added into
2X SDS-PAGE loading buffer in a 1:1 ratio. The samples were boiled for 10 min at 100°C,
loaded onto a 12% Tris-Glycine SDS- PAGE gel, and transferred overnight onto Immobilon
P PVDF membranes (Millipore). Membranes were blocked by 5% non-fat milk, incubated first
with 1 μg/mL anti-PrP Fab D18 and then with goat anti-human IgG F(ab)2 fragment HRP-
conjugated. Blots were developed with the enhanced chemiluminescent system (ECL, Amer-
sham Biosciences) and visualized on Hyperfilm (Amersham Biosciences).
Fluorescence immunostaining of prion amyloid fibril-infected cells
One million cells/mL of each cell line were cultured for 1 day in each well of a 24-well plate
containing a 1.2 cm-coverslip and appropriate culture medium. Medium was removed and
cells were washed with PBS. Cells were fixed for 30min in 4% PFA (paraformaldehyde in PBS)
at RT then washed twice for 15 min with PBS. Fixed cells were blocked in blocking buffer (5%
normal rabbit serum (NRS) in PBS + 0.3% Triton), exposed to anti-PrP monoclonal antibody
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Fab D18 or clone P (10 μg/mL final concentration) for 2 hours. Primary antibodies were made
up in 1% blocking solution and PBS. Cells were washed once with PBS for 15min. The second-
ary antibody used is goat anti-human Alexa 488 at 1:500 dilution in 1% blocking buffer and
PBS. Secondary antibodies were incubated for 1 hour at RT. Finally, cells were washed twice
for 15min with PBS. The coverslips were taken out and dried naturally. The nuclei (blue) were
stained with DAPI, coverslips were mounted in mounting media and subsequently placed on
glass slides and stored at 4°C for confocal fluorescence microscopy.
Measurement of cell viability
Cell viability was examined based on mitochondrial activity, measured by MTT assay. GT1
and N2a cells were maintained in DMEM and EMEM, respectively, and supplemented with
FBS and antibiotics. After 1 day of incubation, media were aspirated from a confluent 10-cm
plate, and cells were detached by adding 1 mL of 1X trypsin-EDTA solution. Media were
added, and cell density determined using a haemacytometer. Cell density was adjusted to
2.5 × 105 cells/mL with media. A 96-well, tissue culture-treated, clear bottom, black plate
(Costar) wetted with 96 μL of media was incubated at 37°C, prior to use. One hundred microli-
ters of cell suspension were added to each well and cells were allowed to settle for 2 hours,
before adding prion amyloid fibrils. Four microliters of prion fibril solutions from different
amyloid preparations in PBS were added to each well (final concentration 2μg/mL of PrP), and
plates were incubated at 37°C in 5% CO2. After incubating for 5 days, media were aspirated
and cells were washed twice with 200 μL of PBS. After treatment with different amyloid sam-
ples, cells were further incubated for 3 hours in fresh media with a final concentration of
0.5 mg/mL MTT. DMSO was added to release the insoluble purple substrates converted by the
active mitochondrial dehydrogenases in the surviving cells. After shaking 30min for solubiliza-
tion, the adsorbance was measured using a SpectraMax M5 plate reader [57].
Intracerebral inoculation of amyloid preparations #4 and #28 (first
passage)
Twenty μl of each amyloid preparation (100 μg of total fibrils) was stereotactically injected in
the striatum of otubred CD1 mice (n = 8). Six week-old CD1 mice (35–40 g) were anesthetized
with tribromoethanol (100 μL/10 g) i.p.-administered and all surgical procedures were per-
formed under sterile conditions. All the animals were sacrificed at 720 days post-inoculation.
PMCA procedures
PMCA was performed as previously described [51]. Briefly, as a substrate, we used brain speci-
mens obtained from outbred CD1 animals. Brains were harvested after perfusion, and 10%
homogenate was prepared in conversion buffer (PBS containing 150 mM sodium chloride and
1% Triton X-100) with the addition of protease inhibitors. Ten μl of raw fibril preprations, cell
lysates from infected cells (P6) or brain homogenates from infected mice were added to the
substrate and transferred in 0.2 mL tubes, positioned on an adaptor placed on the plate holder
of a microsonicator (Misonix, Model S3000) and subjected to 96 cycles of PMCA. Each cycle
(also referred as PMCA round) consisted of 29 min and 40 sec of incubation at 37/40°C fol-
lowed by a 20 sec pulse of sonication set at potency of 260–270 Watt. After one round of
PMCA, an aliquot of the amplified material was diluted 10-folds into fresh substrate and a fur-
ther PMCA run performed following the same procedure. To increase PMCA efficiency, teflon
beads (n = 3) were added to the samples before each round of amplification. To avoid samples
cross-contamination between each round, thorough decontamination of instruments and
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equipment was performed using 2N sodium hydroxide (NaOH) or 4M guanidine hydrochlo-
ride (Gdn-HCl).
Neuropathological analysis
Brains and other organs were fixed in Alcolin (Diapath), dehydrated and embedded in para-
plast. Seven-micrometer thick serial sections were stained with hematoxylin-eosin (H&E) and
thioflavine S, or immunostained with monoclonal antibodies to PrP (6H4), and polyclonal
antibodies to astrocyte activation (GFAP) and microglial activation (Iba-1). Before PrP immu-
nostaining the sections were sequentially treated with proteinase K (10 μg/mL, 5 min) and gua-
nidine isothiocyanate (3M, 20 min), and non-specific binding was prevented using ARK kit
(Dako). Immunoreactions were visualized using 3–3'-diaminobenzidine (DAB, Dako) as chro-
mogen. Lesion profile was performed according to Fraser H. et al 1968 [58].
Biochemical analysis of brain homogenates
Ten percent (wt/vol) brain homogenates from frozen tissues were prepared in lysis buffer. The
cleared lysate (20 μL) was digested with 50 μg/mL of proteinase K (1 h, 37°C). Proteins were
boiled (100°C, 10 minutes) then fractionated using 12% SDS-PAGE under reducing condition
and transferred into nitrocellulose membranes. Immunoblotting with 6D11 (Covance) diluted
in TBST (0.2 μg/mL), 0.05%-Tween20 was performed. Blots were developed using the ECL
Prime detection system (Amersham) and visualized using a G:BOX Chemi Syngene system.
PNGase experiment
Fifty μl of brain homogenates were digested with PK (100 μg/mL) for 1 hour at 37°C with shak-
ing. PNGase digestion was performed following the instructions provided with the kit (PNGase
F, P0704S, 15.000 units, New England Biolabs). Briefly, 4 μl of 10X glycoprotein denaturing
buffer (provided with the kit) were added to the homogenate and the samples were boiled for
10 minutes at 100°C. Subsequently, 4 μl of G7 buffer (provided with kit), 4 μl of NP-40 (pro-
vided with kit), 4 μl of PNGase F and 4 μl of PBS were added to reach the final volume of 40 μl.
Each sample was incubated 2 hours at 37°C with shaking. The reaction was stopped by adding
NuPAGE LDS sample buffer and Western blotting was performed.
Second passage transmission
Twenty μl of brain homogenate from the animals injected with preparation #4 was stereotaxically
inoculated in the striatum of outbred CD1 mice (n = 10). Six week-old CD1 mice (35–40 g) were
anesthetized with tribromoethanol (100 μl/10 g) i.p.-administered and all surgical procedures
were performed under sterile conditions
Supporting Information
S1 Table. Conditions used for the formation of diverse amyloid preparations in non-
REDOX process. To generate recPrP amyloids with different conformations in non-REDOX
process, the conditions for their formation were systematically altered, including denaturant
concentrations, pH and buffer composition.
(DOCX)
S2 Table. Conditions used for the formation of diverse amyloid preparations in REDOX
process. To generate recPrP amyloids with different conformations in REDOX process, the
conditions for their formation were systematically altered, including denaturant
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concentrations, pH and buffer composition.
(DOCX)
S3 Table. Different height of clusters of recMoPrP (23–231) aggregates. Different amyloid
preparations of recMoPrP(23–231) showed aggregate clusters of different heights.
(DOCX)
S1 Fig. Diagram of recMoPrP(23–231) conversion to amyloid. Schematic diagram for the
conversion of the monomeric recMoPrP(23–231) to an amyloid form by REDOX process.
(TIF)
S2 Fig. Lag phase distribution using different conditions (REDOX vs non-REDOX). Lag
phase distribution of amyloid preparations following non-REDOX and REDOX processes
compared to pH 5.0 and pH 7.5. (, P<0.01, n = 12). Bars indicate standard deviation.
(TIF)
S3 Fig. AFM characterization of different synthetic amyloid fibrils. The morphology-depen-
dence of the fibrillizations was observed at different denaturant concentrations. AFM imaging
at the end of the fibrillization reactions shows different morphologies of amyloid preparations
after 72 hours of fibrillization (A). Correlation of amyloidal morphologies and Gdn-HCl con-
centrations in fibrillizations (B).
(TIF)
S4 Fig. PK digestion assay of different amyloid preparations.Western blotting of PK diges-
tion assay showed partial protease K (PK) resistance of recMoPrP(23–231) amyloid prepara-
tions from non-REDOX (A) and REDOX (B). RecMoPrP(23–231) amyloids (PK- lanes) were
digested with PK at ratio 1:10 (w/w) (PK+ lanes) and 1:1 (w/w) (PK++ lanes). Western blots
were performed using Fab D18 monoclonal antibody (1μg/mL). Blots were developed with the
enhanced chemiluminescent system (ECL, Amersham Biosciences) and visualized on Hyper-
film (Amersham Biosciences)
(TIF)
S5 Fig. Seeding assay of N2a and GT1 cell cultures with synthetic amyloid fibrils. Seeding of
recMoPrP(23–231) amyloid preparations induced the conversion of endogenous PrPC into mild
protease K (PK) resistant forms. Western blotting shows the partial PK-resistance of neuroblas-
toma N2a and mouse hypothalamic GT1 amyloid fibril-infected cell lysates. Fibril-infected cell
lysates (PK- lanes) were digested with PK at ratio 1:500 (w/w) (PK+ lanes). Western blots were
performed using Fab D18 monoclonal antibody (1μg/mL) and Clone P (1μg/mL). Blots were
developed with the enhanced chemiluminescent system (ECL, Amersham Biosciences) and visu-
alized on Hyperfilm (Amersham Biosciences)
(TIF)
S6 Fig. PrP accumulation in N2a cell lines. Accumulation of PrP was observed in neuroblas-
toma N2a cell lines infected with different amyloid preparations. The depositions and level of
PrP (green) after six passages (P6) were detected by Fab D18 anti PrP antibody (10 μg/mL final
concentration), using immunofluorescence. The nuclei (blue) were stained with DAPI.
(TIF)
S7 Fig. PrP accumulation in GT1 cell lines. Accumulation of PrP was observed in mouse
hypothalamic GT1 cell lines infected with different amyloid preparations. The depositions
and level of PrP (green) after six passages (P6) were detected by Fab D18 anti PrP antibody
(10 μg/mL final concentration), using immunofluorescence. The nuclei (blue) were stained
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with DAPI.
(TIF)
S8 Fig. MTT assay of N2a and GT1 infected cell lines. Amyloid fibrils of recMoPrP(23–231)
showed mild toxicity in infected-cell cultures. Cell viability based on mitochondrial activity
was measured by MTT assay. Control cells without treatment were counted as 100%. Bars indi-
cate Standard deviation. t-test analysis were performed (, P>0.05, n = 6).
(TIF)
S9 Fig. AFM analysis of amyloid #18. AFM imaging analyses were carried out at the end of
the fibrillization reaction of amyloid preparation #18 (non-REDOX) after 72 hours with 15
minutes of interval-shaking time. AFM scan topographical image of PrP amyloid #18 deposited
on mica surface showed classical forms of diffusion-limited aggregation.
(TIF)
S10 Fig. Immunohistochemical and biochemical assays of amyloid-#4 and amyloid-#28
infected mice (first passage). Neuropathological assessment of CD1 mice injected with prepa-
ration #4 or #28. Immunohistochemical analysis revealed the lack of PrPRes deposition in the
brain associated to mild astroglial activation which is similar to that of the animal injected with
PBS. Scale bar is 10 μm (A). Western blot analysis confirmed the lack of PrPRes deposition in
the brain of injected animals. Samples were digested with PK (100 μg/mL) and immunoblotted
with 6D11 monoclonal antibody to PrP (0.2 μg/mL, Covance) (B). Blots were developed with
the enhanced chemiluminescent system (ECL, Amersham Biosciences) and visualized using a
G:BOX Chemi Syngene system.
(TIF)
S11 Fig. PrPC biochemical profile in wild type animals.Western blot analysis of PrPC bio-
chemical profile in the brain of CD1 mice (dilutions 1:10 and 1:50). Western blots were per-
formed using 6D11 monoclonal antibody to PrP (0.2 μg/mL, Covance). Blots were developed
with the enhanced chemiluminescent system (ECL, Amersham Biosciences) and visualized
using a G:BOX Chemi Syngene system.
(TIF)
S12 Fig. Infectious properties of new batches of amyloid preparations. To assess whether
the infectious amyloid #4 was obtained in a random phenomenon, we have used the same bio-
chemical conditions to produce a new batch of this amyloid (#4) and we have assessed its infec-
tious properties either in cells and by means of PMCA. Atomic Force Microscopy (AFM)
imaging analysis of the new batch of amyloid #4 was performed at the end of the fibrillization
reactions after 72 hours. AFM scan topographical images of prion protein (PrP) deposited on
mica surface, large-scale images (A); Independent fibrillization kinetic experiments with ThT
as fluorescence dye (B); Western blots of amyloid #4 infected cell lysates (N2a and GT1) after
PK digestion (2μg/mL) incubated with the Clone P monoclonal antibody (1 μg/mL final con-
centration) (C); Immunofluorescence staining of amyloid #4-infected N2a and GT1 cells using
anti-PrP monoclonal antibody Fab D18 (10 μg/mL final concentration) (D); Seeding ability of
new batch of amyloid #4 (raw fibril) was assessed by means of PMCA using brain homogenates
of CD1 mice as substrates for amplification. New batches of amyloid #4, #19 and #28 were
inoculated in N2a cells, collected at P6 and amplified in PMCA. Amplification of ScN2a
infected cell lysate was used as internal control for PMCA reaction. Western blots were per-
formed using 6D11 monoclonal antibody to PrP (0.2 μg/mL, Covance). Blots were developed
with the enhanced chemiluminescent system (ECL, Amersham Biosciences) and visualized
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using a G:BOX Chemi Syngene system (E).
(TIF)
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